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Abstract: Studies of alterations in histone methylation in cancer have led to the identification
of histone methyltransferases and demethylases as novel targets for therapy. Lysine-specific
demethylase 1 (LSD1, also known as KDM1A), demethylates H3K4me1/2, or H3K9me1/2 in a
context-dependent manner. In addition to the well-studied role of LSD1 in the epigenetic regulation of
histone methylation changes, LSD1 regulates the methylation dynamic of several non-histone proteins
and participates in the assembly of different long noncoding RNA (lncRNA_ complexes. LSD1 is
highly expressed in various cancers, playing a pivotal role in different cancer-related processes. Here,
we summarized recent findings on the role of LSD1 in the regulation of different biological processes
in cancer cells through dynamic methylation of non-histone proteins and physical association with
dedicated lncRNA.
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1. Introduction
Considerable efforts have been placed to understand how changes in the epigenome contribute to
cancer progression [1,2]. Accordingly, enzymes that control epigenetic marks have been investigated
as potential targets for cancer therapy [3,4]. It is widely accepted that chromatin modifiers play an
important role in tumorigenesis [1–4]. Histone acetylation generally correlates with transcriptional
activation [5], while histone methylation serves as activating or repressive transcriptional marker,
depending on the location and degree of residue methylation [6]. Methylation may occur on both
arginine and lysine residues and creates docking sites for recognition and binding of so-called reader
proteins [7].
The demethylase 1 (LSD1/KDM1A) lysine-specific demethylase 1 is an epigenetic enzyme
whose overexpression is correlated with poor prognosis in a variety of cancers [8–12] and has been
proposed as therapeutic target [13]. LSD1 demethylates mono- or di-methyl-lysine 4 or 9 of histone H3
(H3K4me1/me2 and H3K9me1/me2, respectively) depending on its interacting partners [14–20].
LSD1 (KDM1A/AOF2), with LSD2 (KDM1B/AOF1), is a member of the flavin-dependent
LSD/KDM1 demethylase protein family. Both enzymes contain the Swi3p, Rsc8p, and Moira
(SWIRM) and amine oxidase (AO) domains. Structurally, LSD1 contains a coiled-coil Tower
domain protruding from the AO domain responsible for interaction with its co-factors, while
LSD2 possesses the amino-terminal zinc finger element that is necessary for LSD2 binding to its
methylated substrate [21]. Although LSD1 and LSD2 share significant homology and both enzymes
demethylate lysine 4 on histone 3 in a flavin adenosine dinucleotide (FAD)-dependent manner, the
two enzymes have distinct functions, affecting different steps of the gene transcription. Genome-wide
chromatin-immunoprecipitation studies have shown that LSD1 binds to the enhancer and promoter
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regions of genes [22,23]; in contrast, LSD2 associates primarily with the body regions of actively
transcribed genes [21,24].
A large number of studies have highlighted the pivotal role of LSD1 in several cellular processes
in normal and cancer cells such as control of stemness, differentiation [12,22,23], cell motility,
epithelial-to-mesenchymal transition [10,25,26], autophagy [9,27], senescence [28], neurodegenerative
diseases [29,30], and metabolism [31]. To achieve these widespread biological functions, LSD1 is a
component of different multi-protein complexes and its association with over 60 gene regulatory
proteins has been demonstrated [14,15,32–34].
While the role of LSD1 as an epigenetic master regulator of the transcription (co-activator
or co-repressor) has been well explored, its function in the methylation dynamics of several
non-histone proteins and in the assembly of different long noncoding RNA (lncRNA) complexes
is an emerging field.
This review will be focused on the increasing recent evidences that characterize LSD1 as a
functional regulator of non-histone proteins and lncRNAs in the biology of cancer cells.
2. LSD1 as Transcriptional Coregulator
LSD1 was first isolated as the interacting partner of the CoREST (RCOR1) transcription repressor
complex [35] and the histone deacetylase HDAC1/2 [36]. In complexes with CoREST and NuRD
(Nucleosome Remodeling and Deacetylase), LSD1 demethylates monomethyl and dimethyl histone
H3 lysine 4 (H3K4me1/me2), which mark an active chromatin transcription state [37–42] (Figure 1a).
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Figure 1. (a) Demethylase 1 (LSD1) is recruited at the target gene by a wide number of transcription
factors (indicated in figure) where it promotes the transcriptional repression through demethylation of
the H3K4me2 activation mark. (b) LSD1 demethylates the repressive mark H3K9me2 as coactivator
with the androgen or estrogen receptor. (c) LSD1+8a, a neuronal-specific isoform, catalyzes the
demethylation of the repressive mark H4K20me2, by interacting with CREB and MEF2.
LSD1 represses the transcription process and interacts with members of the SNAG domain of
transcription factors such as SNAIL1/2 and GFI1/B. The LSD1-CoREST complex, through interaction
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with the SNAG domain of SNAIL, is recruited to the E-cadherin (CDH1) promoter to remove methyl
groups on lysine 4 of histone H3 resulting in repression of its expression [43].
Despite its well-reported activity as transcription repressor, LSD1 is also a co-activator of the
androgen (AR) and estrogen (ER) receptor-dependent transcription. The interaction between LSD1 and
AR or ER nuclear receptors directly or indirectly modify its substrate specificity through demethylation
of the repression-associated H3K9me1/2 mark [15,16] (Figure 1b). Moreover, it has been proposed that
LSD1 recruitment by ER or c-Myc on target genes triggers DNA oxidation and recruitment of base
excision repair enzymes that favor chromatin looping of transcriptional activation [14,15].
Different behavior and tissue specificity have been addressed to the splicing variant of LSD1
(LSD1+8a) containing four additional amino acids (exon 8a) within the AO domain [44]. The presence of
exon 8a generates a docking site for supervillain (SVIL) converting LSD1 into an H3K9 demethylase in
neuronal differentiation [45]. Moreover, LSD1+8a has also been described to promote the transcription
of neuronal-regulated genes by removing H4K20me2 (Figure 1c) [46]. Intriguingly, LSD1+8a activity is
required for memory and spatial learning [46].
Finally, the LSD1 protein is target of different post-translational modifications that alter its activity
or stability expanding its possibility to exert different roles in transcription regulation [8,47]. LSD1
phosphorylation at serine 112 by the PKCα (Protein kinase C alpha) is crucial for its recruitment
on E-cadherin promoter [48]. Moreover, LSD1 acetylation by the acetyltransferase MOF is specific
of epithelial cells and seems to be critically involved in LSD1-induced epithelial to mesenchymal
transition (EMT) [49].
3. LSD1 and Cancer
LSD1 has been proposed as a druggable target in cancer for a large number of observations
reporting its high expression levels in poor prognosis of prostate, lung, brain, and breast cancers,
as well as in certain hematologic malignancies [13]. Accordingly, different LSD1 inhibitors are
currently in clinical trial studies [13,50]. In addition, it has been recently reported that high rates
of germline truncating and missense LSD1 mutations occur in multiple myeloma (MM), suggesting
that LSD1 is an autosomal dominant MM predisposition gene [51]. It is plausible that LSD1, through
interaction with different factors, might exert distinct molecular mechanisms in various tumor types.
Nevertheless, LSD1 plays important role in cellular processes shared by different cancers such as EMT,
as comprehensively described in recent reviews [26,27].
Notably, the paradigmatic role of LSD1 in cancer, based on its histone demethylation capacity,
has been questioned in two recent reports [22,52]. LSD1 is significantly expressed in less differentiated
subtypes of acute myeloid leukemia (AML), and several data support the oncogenic potential of
LSD1 in AMLs, and in particular, its capacity to sustain leukemia stem cells [22]. Intriguingly, in a
recent work, Maiques-Diaz et al. [22] remarkable discovered that LSD1 promote the differentiation in
AML through mechanisms that are histone demethylases activity independent. Specifically, inhibition
of LSD1 results in the functional inactivation of transcription repressor GFI1 with disruption of
GFI1-LSD1-RCOR1 interaction [22,53].
In prostate cells, Sehrawat et al. [52] showed that LSD1 promotes survival of castration-resistant
prostate cancer cells, independently of its demethylase function. Inactivation of LSD1 increased the
expression of a subset of androgen receptor (AR) target genes. Furthermore, the authors suggest that
the effects of LSD1 on cell survival are explained in part by the activation of a lethal prostate cancer
gene network in collaboration with the binding protein ZNF217 [52].
Whether such demethylase-independent mechanisms are conserved in other malignancies needs
further investigations.
4. Non-Histone Substrates of LSD1
Although LSD1 was originally identified as histone lysine demethylase, several reports
highlight the role of LSD1 to regulate the activity of non-histone proteins through LSD1-dependent
Cancers 2019, 11, 324 4 of 15
demethylation mechanisms. Indeed, LSD1 participates to the methylation/demethylation dynamics
on specific lysine residues of several non-histone proteins, including, p53, DNMT1, STAT3, E2F1,
RB1, MEFD2, MTA1, ERα, HSP90, HIF-1α, and more recently AGO2 (Figure 2) [12]. The demethylase
activity of LSD1 alters both the function and stability of the aforementioned proteins. Specifically,
LSD1 enhances STAT3 and p53 functional activity without changes in their expression levels, whereas
it destabilizes the protein MYPT1 and stabilizes E2F1, MEFD2 and HIF-1α proteins.
Understanding how the demethylation of lysine residues of non-histone proteins by LSD1
influences different cellular processes is an emerging field in the biology of cancer cells.
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Figure 2. LSD1 regulates methylation dynamics of non-histone proteins.
4.1. LSD1 Modulates the Activity of Cell-Cycle Regulators
The first discovered target of LSD1 demethylation was p53 [54], one of the most important tumor
suppressor proteins. p53 controls different cellular stress signals, in particular, it activates transcription
targets involved in the control of cell cycle and apoptosis. After DNA Damage, p53 is phosphorylated
by ATM (Ataxia Telangiectasia Mutated) and induces p21 transcription with consequent cell cycle
arrest. p53 is regulated by MDM2 (Murine Double Minute 2), which binds p53 and determines its
proteasome dependent degradation. Moreover, there is a dual relationship between MDM2 and p53.
Indeed, MDM2 itself is positively regulated by p53, which functions as a transcriptional factor of the
mdm2 gene. p53 is methylated by SMYD2 on lysine 370 (K370me1/me2); this modification is required
for its association with the co-activator p53 Binding Protein 1 (53BP1) [54,55]. LSD1 demethylates p53
K370me1/me2, thus inhibiting its binding to DNA and its pro-apoptotic activity (Figure 3a) [54].
LSD1 also regulates DNA damage-induced cell death demethylating E2F1 lysine 185 (K185) in
p53-deficient cancer cells [56]. LSD1 maintains unmethylated E2F1 in the cells, which can be upon DNA
damage hyperacetylated and phosphorylated by PCAF and CHK2, respectively. E2F1 hyperacetylated
and phosphorylated cannot be methylated on K185 by Set9 and, escaping degradation, accumulates
in the cells to promote apoptosis (Figure 3a). Finally, the demethylation activity of LSD1 promotes
DNA damage-induced cell death by stabilizing E2F1 in p53-deficient tumor cells, whereas it inhibits
apoptosis repressing p53 transcriptional activity [56,57].
The role of LSD1 in the cell cycle is also supported by its activity toward the retinoblastoma
protein (RB1) [58]. Cell-cycle phosphorylation dynamics of RB1 is required for proper control of cell
cycle progression and low levels of RB1 restrict cells ability to replicate DNA with cell division arrest
in the G1 phase. RB1 is dephosphorylated by the phosphatase PPP1R12A (also known as MYPT1).
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However, PPP1R12A lysine 442 is methylated by the histone lysine methyltransferase SETD7 and
demethylated by LSD1. LSD1-mediated demethylation of PPP1R12A enhances its polyubiquitylation
and proteasome degradation and therefore increases the levels of phosphorylated RB1 (Ser 807/811)
promoting cell cycle progression (Figure 3b) [58].
Taken together, these findings support the role of LSD1, as a modulator of the methylation/
demethylation dynamic of RB1, into the cell cycle regulatory mechanism and human carcinogenesis.
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Figure 3. LSD1-dependent demethylation regulates activity of non-histone proteins. Effects of
LSD1-mediated demethylation of non-histone proteins p53-E2F1 and PPP1R12A (a), HIF-1α (b), and
AGO2 (c).
4.2. LSD1-Mediated Demethylation Regulates HIF-1α Function
Relevant in cancer progression is the functional interaction between LSD1 and HIF-1α
(Figure 3c) [59–62]. HIF-1α plays a crucial role in the development of aggressive cell phenotype
(through stimulation of angiogenesis, epithelial-mesenchymal transition, and invasion) and in
glycolytic and mitochondrial metabolism interplay. Among the various post-translation modifications,
HIF-1α is methylated by the SET7/9 histone methyltransferase at lysine 32 residue (K32) [60]. Moreover,
SET9 methylases the HIF-1α lysine 391 (K391) [62], and that determines the HIF-1α ubiquitin-mediated
protein degradation. HIF-1α K32 and K391 methylated residues are demethylated by LSD1 [60,62].
In addition, HIF-1α is hydroxylated at proline 402 and 564 residues (P402/564) and such modifications
are required for methylation of K391. HIF-1α hydroxylation, as well as its methylation, is directly
suppressed by LSD1. Thus, LSD1 prevents HIF-1α ubiquitination and degradation by inhibiting both
hydroxylation and methylation [62]. Moreover, LSD1 further controls HIF-1α protein stability, in an
FAD-dependent manner, demethylating the lysine 271 residue (K271) of RACK1 protein, a component
of the HIF-ubiquitination complex. The demethylation of RACK1 impairs its binding to HIF-1α and
suppresses RACK1-mediated HIF-1α degradation [61].
Cancers 2019, 11, 324 6 of 15
LSD1, through HIF-1α stabilization, induces genes involved in glycolysis in cancer cells [31].
LSD1 directly represses genes involved in mitochondrial metabolism demethylating histones H3K4
(Figure 3c).
LSD1 plays a key role in the reprogramming of cancer metabolism inducing the shift from
oxidative to glycolytic metabolism, maintenance of redox homeostasis, and cell survival.
4.3. LSD1 and Immunogenicity
Recent studies discovered a novel function of LSD1 in modulating the tumor immunogenicity.
Work from Sheng’s [63] laboratory has shown that LSD1, through demethylation of AGO2
(Protein Argonaute 2) has a crucial role in the suppression of anti-tumor immunity and tumor
immunogenicity [63].
AGO2 is a core element of the RNA-inducing silencing complex (RISC) and directly initiates
degradation of target RNAs through its catalytic activity. AGO2 protein stability depends on LSD1
demethylation of its lysine 726 residue (K726). In breast and melanoma cells, it has been demonstrated
that LSD1 inhibition reduces RISC activity, via methylation-dependent de-stabilization of AGO2,
and concomitantly increases endogenous retroviral (ERV) expression, leading to dsRNA stress
(Figure 3c) [63]. RNA stress determines activation of type 1 interferon (IFN) response that consequently
sensitizes tumors to T cell immunity and T cell infiltration into melanoma tumors [63]. Moreover, LSD1
ablation in these tumor cells results in the upregulation of PD-(L)1, the programmed death-ligand
1, which might compromise the anti-tumor effect of T cells infiltration. Indeed, PD-(L)1, expressed
on cancer cells, binds PD-1 (programmed death-1), expressed on the surface of immune cells, and
forms a biochemical “shield” protecting tumor cells from being destroyed by the immune system.
Conversely, in LSD1-KO tumors, upregulation of PD-1 renders refractory tumor responsive to anti-PD-1
therapy [63]. Thus, LSD1 inhibition and concomitant PD-1 blockade have shown a synergistic effect in
the reduction of tumor growth [63].
Very recently, Qin et al. [64] reported the role of LSD1 in regulation of breast tumor
immunogenicity. LSD1 inhibition increases the expression of key immune checkpoint regulators
such as CCL5, CXCL9, and CXCL10 and effector T cell chemokines, which in turn increases CD8+ T
cell tumor infiltration and improves the efficacy of immunotherapy [64]. This study further supports
the potential role of LSD1 inhibition in cotreatment with immunotherapy as a novel management
strategy for poorly immunogenic breast tumors.
In conclusion, LSD1 inhibition could be instrumental to convert “cold” tumors (resistant to PD-1
blockade) in “hot” tumors (responsive to PD-1 therapy) and provides a means to target LSD1 to
increase the efficacy of immunotherapy of poor immunogenic cancers.
5. LSD1 and lncRNA
Long noncoding RNAs (lncRNAs) are emerging classes of regulatory RNAs that operate as
pivotal modulators in different molecular processes such as gene regulation, maintenance of genome
packaging, chromatin dynamics, and cell differentiation. Recent studies propose lncRNAs as players
in regulation of gene expression in immune cells and in a variety of human diseases, including cancers.
Indeed, lncRNAs are involved in cancer development through different pathways; specifically, their
deregulation induces cancer cells to initiate tumor growth and metastatic processes [65]. Various
evidences have indicated that several lncRNA contribute to cancer cell phenotypes through the
interaction with chromatin-modifying agents and proteins, such as the polycomb repressive complex
2, LSD1, CoREST, and SMCX.
Here, we highlight the role of LSD1 through functional and physical interaction with a plethora
of lncRNAs (Table 1 and Figure 4).
Cancers 2019, 11, 324 7 of 15
5.1. LSD1 and lncRNA HOTAIR
HOTAIR (HOX antisense intergenic RNA) is an lncRNA originally discovered by Rinn et al. [66]
that acts as a modular scaffold to induce gene silencing by regulating chromatin dynamics [67].
HOTAIR regulates cell cycle progression and its expression is correlated with poor prognosis in
breast, pancreatic, and colon cancer patients [68]. The mechanism by which HOTAIR regulates gene
expression has been elucidated; it has been found that HOTAIR acts as scaffold of various different
complexes involved in different types of human cancers. Its epigenetic role is exerted through its
association with two histone modifiers: while the 5′ domain of HOTAIR binds the histone methylase
PRC2, the 3′ domain scaffolds the histone demethylase LSD1. Such complexes are recruited to
target gene loci resulting in transcription repression via H3K27-trimethylation (PRC2 activity) and
H3K4-demethylation (LSD1 activity) (Figure 4a) [68,69].
Table 1. List of long noncoding RNAs (lncRNAs) that interact with LSD1 in several cancers.
lncRNA Tumor Reference
HOTAIR Breast, Pancreatic andGlioblastoma [68–72]
TERRA Cervical [73–79]
SRA Breast [80–83]
Linc00673 Gastric [84]
FOXD2-AS1 Gastric [85]
HOXA11-AS Gastric [86]
HOTTIP Renal Cell Carcinoma [87]
Linc01133 Non-small cell lung [88]
FEZF1-AS Non-small cell lung [89]
HOXA-AS2 Pancreatic and Colorectal [90,91]
IRAIN Pancreatic [92]
SPRY4-IT1 Cholangiocarcinoma [93]
FOXP4-AS1 Osteosarcoma [94]
SUZ12
EEDEZH2
PRC2 complex
5’
CoREST
RESTLSD1
3’ DemethylationMethylation
LSD1 complexHOTAIR
Me3K27Me3K27 Me2K4Me2K4Me3K27 Me3K27
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Figure 4. (a) HOTAIR mediates target gene silencing; it binds to PRC2 complex (EZH2, SUZ12,
EEDs) and LSD1 complex (CoREST/REST) through binding at 5′ and 3′ ends, respectively, regulating
trimethylation of H3K27me3 and demethylation of H3K4me2. (b) TERRA RNA modulates telomeric
gene silencing through recruitment of LSD1 on uncapped telomeres, reinforcing the interaction between
LSD1 and MRE11. (c) SRA interacts with the repressive complex LSD1-HP1γ-HDAC1/2-CoREST
(LSD1.com) and brings this complex on target chromatin, promoting aberrant hormone-regulated
gene expression.
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It has been found that in pancreatic cancers, HOTAIR-mediated gene repression is both
PRC2-dependent [70] and independent [71]; however, in glioma cells, HOTAIR regulates cell cycle
progression predominantly via the PRC2 axis (EZH2-dependent) [70]. Moreover, in breast cancers,
HOTAIR functions as scaffold for LSD1 and HBXIP (Mammalian hepatitis B X-interacting protein) on
c-Myc target genes [72]. HBXIP is found highly expressed in breast cancer and it generally regulates the
expression of genes involved in cancer growth and metastasis interacting with different transcription
factors (TF-II, STAT3, E2F1, SP1, and c-Myc). In particular, the oncoprotein HBXIP interacts directly
with c-Myc leading to the recruitment of HBXIP-HOTAIR-LSD1 complex on the E-box of c-Myc target
genes and determines their activation [72].
These findings reveal that targeting HOTAIR might be an innovative therapeutic strategy aimed
to disrupt HBXIP-HOTAIR-LSD1 function.
5.2. LSD1 and lncRNA TERRA
TERRA (Telomeric Repeat containing RNA) is an lncRNA which is transcribed from subtelomeres
toward chromosome ends by RNA Polymerase II, where it remains partly associated with telomeric
chromatin and plays a key role in telomere length control. Furthermore, TERRA modulates telomeric
gene silencing through recruitment of the demethylase (LSD1) and the methyltransferase (SUV39H1)
that regulate H3K4/K9 methylation patterns [73–76]. TERRA binds the SWIRM/AOL-N-terminal
domain of LSD1, this interaction stabilizes LSD1 binding at dysfunctional chromosome; subsequently,
RNA-LSD1 interaction activates MRE11, which through its nuclease activity trims the 3′G overhangs at
uncapped telomeres. MRE11 acts in sensing dysfunctional telomerase by promoting ATM-dependent
DNA-damage signaling (Figure 4b) [77].
These findings highlight that the interaction between LSD1 and lncTERRA controls the telomere
length with a strong impact in aging and cancer [77,78]. It is pertinent to note that TERRA is
overexpressed in different types of cancer. TERRA accumulates and forms TERRA foci (TERFs)
in highly proliferating progenitors and in human medulloblastoma tissue [79], suggesting that TERFs
may provide a novel and sensitive biomarker for telomere dysfunction in cancer.
5.3. LSD1 and lncRNA SRA
In breast cancer cells the lncRNA SRA (Steroid Receptor RNA Activator), originally identified
in human B-lymphocyte [80], plays a scaffolding role bringing together the repressive complex
LSD1-HP1γ-HDAC1/2-CoREST-KDM5B, referred as HP1 γ-LSD1 complex [81,82]. In breast cancer
cells, SRA can function as central platforms for the assembly of different molecular components. It has
been demonstrated that SRA, interacting with HP1 γ-LSD1 complex and anchoring this repressive
complex on target chromatin, promotes aberrant progesterone-regulated gene expression and affects
hormone-dependent proliferation and apoptosis (Figure 4c) [81,82]. Recently, it has also been found
that the HP1γ-LSD1 complex is recruited, through interaction with the ATP-dependent remodeling
protein BRG1, by ligand-activated progesterone receptor (PR) to transcriptionally repressed genes
involved in cell proliferation [83].
These findings suggest the targeting of the HP1γ-LSD1 complex for the management of
hormone-dependent cancers.
5.4. LSD1 and the Oncogenic lncRNAs
A growing list of studies has underlined the scaffolding role of the lncRNAs for epigenetic
enzymes as LSD1 and EZH2 to form ribonucleoprotein complexes capable to repress the transcription
of tumor suppressor gene. Then, the lncRNA-LSD1/EZH2 complexes exert oncogenic function and
promote tumor development and progression (Table 1).
In gastric cancer cells, three lncRNAs (LINC00673, FOXD2-AS1, HOXA11-AS) have been identified
to interact with LSD1 and EZH2. In particular, the lncRNAs LINC00673 [84] and FOXD2-AS1 [85],
in association with LSD1 and EZH2 repress, LAST2/KLF2 and EphB3 tumor suppressors, respectively.
Cancers 2019, 11, 324 9 of 15
The HOXA11-AS (homeobox HOX A11 antisense mapping at the HOXA gene cluster) lncRNA
scaffolds the chromatin modification factors PRC2, LSD1, and DNMT1 to regulate PRSS8 and KLF2 at
transcriptional levels [86]. Another member of the HOXA gene cluster, HOTTIP, through binding to
LSD1 and EZH2, represses LAST2 expression in renal cell carcinoma [87].
In non-small cell lung cancer (NSCLC) two lncRNAs have been found to exert oncogenic function
interacting with EZH2 and LSD1: Linc01133, which regulates the transcription of KFL2, p21 and
E-cadherin controlling cell proliferation, migration and invasion as well as apoptosis [88]; and
FEZF1-AS that epigenetically represses the expression of E-cadherin enhancing EMT process [89].
In pancreatic cancer cells (PC) and colorectal cancer tissue (CRC), HOXA cluster antisense RNA2
lncRNA (HOXA-AS2) is involved in cell growth forming a complex with LSD1 and EZH2 [90,91].
The knockdown of HOXA-AS2 blocks the cell cycle transition and then provokes apoptosis, repressing
p21 and KFL2 transcription. In PC cells, the lncRNA IRAIN forms a complex with LSD1 and EZH2,
suppressing apoptosis and promoting proliferation [92].
Finally, in cholangiocarcinoma (CCA) and in osteosarcoma tumors (OS), the SPRY4-IT1 [93]
and FOXP4-AS1 [94] lncRNAs, have been shown to play a role in tumor growth. Mechanistically,
SPRY4-IT1 recruits EZH2 and LSD1 or DNMT1 to KLF2 and LATS2 promoter regions inducing
epigenetic silencing [93]. Conversely, FOXP4-AS1 lncRNA, in complex with LSD1 and EZH2, sustains
OS cell growth by repressing LATS1 transcription [94].
Collectively, these findings highlight the oncogenic function of specifics lncRNAs, suggesting that
they may represent novel targets for therapy in the several human cancer diseases.
6. Conclusions
LSD1 constitutes a promising epigenetic target to treat different malignancies. Accordingly,
many clinical trials using diverse LSD1 inhibitors are currently underway [13,50]. However, despite
significant progress in understanding structural-functional aspects of LSD1 function, the molecular
mechanisms underlying its involvement in cancer biology are not firmly established.
LSD1 was originally defined as a histone ‘eraser’ capable to demethylate H3K4m1/2 and
H3K9me1/2 [14–20]. Chromatin immunoprecipitation studies established that LSD1 is present
at enhancers and transcriptional start sites (TSS) of a large number of Polymerase-II-dependent
genes [22,23]. The current paradigm suggests that LSD1 is recruited at enhancer chromatin regions
thought interaction with multi-protein complexes containing a specific DNA-binding transcription
factor. Accordingly, it is well established that LSD1 is present in a large number of transcription factors
complexes affecting several biological functions depending upon the specific complex in which LSD1 is
present [14–20,22,23,25,34,35,43,54–61]. The current assumption is that LSD1 is recruited at regulatory
chromatin sites thought association with dedicated DNA-binding transcription factors. A number
of evidences have clearly demonstrated that LSD1 can be recruited at specific targets via formation
of riboprotein complexes containing lncRNAs, which act as modular scaffold of different histone
modulators, including LSD1, in different type of human cancers.
An additional expanding role of LSD1 in cancer comes from the discovery of the capability
of LSD1 to regulate activity of non-histone proteins as a result of LSD1-dependent demethylation
mechanisms. Thus, LSD1 affects the methylation/demethylation dynamics on specific lysine residues
of several non-histone proteins. It is conceivable that the multifaceted functions of LSD1 might account
for its role in several different cellular processes in normal and cancer cells [66–94].
It is important for future studies to consider the methylation-demethylation dynamics of LSD1
histone substrates in order to establish the LSD1 function to epigenetic plasticity, and how LSD1 could
contribute to cancer-associated epigenomic changes. In addition, the capability of LSD1 to modulate
the methylation status of several important non-histone substrates, involved in cellular homeostasis,
extends the role of LSD1 in several cellular processes which are deregulated in cancer.
We expect that a deeper characterization of the molecular functions of LSD1 in cancers will pave
the way to the development of novel strategies for innovative treatment of cancer.
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